Sylvester Comprehensive Cancer Center

  • 20221294 - Avisar Eli

  • Investigator:
    Eli Avisar
    RCname Email

    Coordinator:

    IRB: 20221294

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: SBI ALApharma Canada Inc

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    A prospective multi-center clinical study evaluating the use of PD G 506 A and the Eagle V1.2 Imaging System for the visualization of carcinoma during breast conserving surgery

    Eligibility Criteria - NCT04815083 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220314 - Escobar Mauricio

  • Investigator:
    Mauricio Escobar
    RCname Email

    Coordinator:

    IRB: 20220314

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: Greenwich LifeSciences Inc

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adju

    Eligibility Criteria - NCT05232916 *This information has been extracted from " www.clinicaltrials.gov"

  • RPL-001-16 - Hernandez Aya, Leonel

  • Investigator:
    Leonel Hernandez Aya
    RCname Email

    Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone +1 (786) 5828551

    IRB: 20180802

    SDG: Breast Cancer
    Disease Site(s):

    Bladder,Breast-Female,Colon,Melanoma, skin,Other Skin

    Sponsor: REPLIMUNE

    Enrolling Sites:

    Sylvester

    Title:

    RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors

    Eligibility Criteria - NCT03767348 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201540 - Kesmodel Susan

  • Investigator:
    Susan Kesmodel
    RCname Email

    Coordinator:

    IRB: 20201540

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: SCCC

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    Prospective Evaluation of Targeted Axillary Dissection After Neoadjuvant Systemic Therapy in Patients with Breast Cancer with Advanced Nodal Disease at Diagnosis

    Eligibility Criteria - NCT04998682 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221166 - Krill Jackson Elisa

  • Investigator:
    Elisa Krill Jackson
    RCname Email

    Coordinator:

    IRB: 20221166

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: SCCC

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    Free-HER: Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer

    Eligibility Criteria - NCT05959291 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220744 - Perez Alejandra

  • Investigator:
    Alejandra Perez
    RCname Email

    Coordinator:

    IRB: 20220744

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: ETCTN

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    Randomized phase 2 clinical trial of nab-paclitaxel + durvalumab (MEDI4736) + tremelimumab + neoantigen vaccine vs. nab-paclitaxel + durvalumab (MEDI4736) + tremelimumab in patients with metastatic triple negative breast cancer

    Eligibility Criteria - NCT03606967 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230138 - Perez Alejandra

  • Investigator:
    Alejandra Perez
    RCname Email

    Coordinator:

    IRB: 20230138

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: Gilead Sciences, Inc.

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    UMH

    Title:

    A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer, Wh

    Eligibility Criteria - NCT05382286 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230330 - Perez Alejandra

  • Investigator:
    Alejandra Perez
    RCname Email

    Coordinator:

    IRB: 20230330

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: ASTRA ZENECA

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer

    Eligibility Criteria - NCT05774951 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230888 - Perez Alejandra

  • Investigator:
    Alejandra Perez
    RCname Email

    Coordinator:

    IRB: 20230888

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: Gilead Sciences, Inc.

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

    Eligibility Criteria - NCT05633654 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221120 - Rojas Kristin

  • Investigator:
    Kristin Rojas
    RCname Email

    Coordinator:

    IRB: 20221120

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: SCCC

    Enrolling Sites:

    Plantation
    Sylvester

    Title:

    A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause

    Eligibility Criteria - NCT05812924 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210118 - Valdes Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:

    IRB: 20210118

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: Alliance

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib

    Eligibility Criteria - NCT04457596 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221297 - Valdes Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:

    IRB: 20221297

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: SCCC

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients with Metastatic (Stage IV) Breast Cancer: A Phase 2 Randomized, Open-Label Study

    Eligibility Criteria - NCT05826964 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231043 - Valdes Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:

    IRB: 20231043

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: NRG

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score

    Eligibility Criteria - NCT05879926 *This information has been extracted from " www.clinicaltrials.gov"